story of the week
Nivolumab Provides Durable Responses in Patients With Metastatic DNA Mismatch Repair–Deficient or MSI-High Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nivolumab in Patients With Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study
Lancet Oncol 2017 Jul 19;[EPub Ahead of Print], MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, J Desai, A Hill, M Axelson, RA Moss, MV Goldberg, ZA Cao, JM Ledeine, GA Maglinte, S Kopetz, T AndréFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.